FDA Approves Feraheme™ To Treat Iron Deficiency Anaemia In Person Chronic Kidney Disease Patients

NASDAQ:AMAG) announced that the U.S. Nourishment and Narcotic Authority (FDA) has granted marketing approval for Feraheme™ (ferumoxytol) Injection for intravenous (IV) operate as an iron replacement therapy for the treatment of iron deficiency anemia in man patients with chronic kidney disease. Feraheme should be administered as an undiluted IV injection delivered at a percentage of up to 1 mL sec (30 mg sec). The recommended Feraheme Potion may be readministered to patients with persistent or recurrent iron deficiency anemia.

Feraheme is expected to be commercially available in the U.S. The middle of summer 2009. Feraheme Testament be distributed primarily wholesalers and speciality distributors. Feraheme offers patients across the continuum of chronic kidney disease, including patients not on dialysis and patients on dialysis, a advanced model for the treatment of iron deficiency anemia," commented Brian J.G.

Pereira, MD, Head of the state and Manager Executive Officer of AMAG. We are awfully Satisfied with the FDA's approval of Feraheme, and we are bushy-tailed prepared and aroused to bring this au courant treatment alternative to patients and physicians." We receive the availability of a dissimilar therapy possibility for chronic kidney disease patients affected by iron deficiency anemia."

Clinical Material Feraheme has been proven to be a guarded and efficacious therapy for treating iron deficiency anemia in mortal chronic kidney disease patients. The FDA approval of Feraheme was based on safety and efficacy results from four Page III studies of patients with chronic kidney disease and iron deficiency anemia.

These studies consisted of three accessible-sticker, multi-centre, randomized safety and efficacy clinical studies and a fourth twofold-blind, multi-center, randomized, placebo-controlled cross-over safety glance at.

Feraheme significantly increased haemoglobin levels as compared to spoken iron across the spectrum of chronic kidney disease.

In accordance with the Paediatric Proof Fairness Circumstance (PREA) requirement, the Firm will regulate two publish-marketing studies in the pediatric chronic kidney disease population; one in patients on dialysis and the other in patients not on dialysis.

Everyone interpret will enrol on all sides of 75 subjects, collecting pharmacokinetic, safety and efficacy info as compared to vocal iron. The Partnership expects to open these studies in 2010. Articles All 'How To..